United States pharmaceutical maker, Pfizer, and biopharmaceutical company, Global Blood Therapeutics (GBT), on Monday, agreed that Pfizer would acquire GBT in an all-cash deal valued at 5.4 billion U.S. dollars.
Pfizer said the acquisition would drive growth by enhancing its work in rare hematology while reinforcing the company’s commitment to sickle cell disease research and treatment.
According to dpa, under the terms of the transaction, Pfizer will acquire all the outstanding shares of California-based GBT for 68.50 dollars per share in cash, for a total enterprise value of approximately 5.4 billion dollars, including debt and net of cash acquired.
READ ALSO: BioNTech, Pfizer to develop vaccine against shingles
The pharmaceutical company expects to finance the transaction with existing cash on hand.
The proposed transaction, unanimously approved by the Boards of Directors of both companies, is subject to customary closing conditions, including receipt of regulatory approvals and approval by GBT’s stockholders.
Troops of Sector 5 of the Joint Task Force South-East, Operation UDO KA, working alongside…
Nigerian singer Oluwatosin Ajibade, well known as Mr Eazi, and his wife, Temi Otedola-Ajibade, have…
President of the Senate, Godswill Akpabio, on Wednesday administered the oath of office to four…
The operatives of the National Drug Law Enforcement Agency (NDLEA) have uncovered a methamphetamine laboratory…
The Federal High Court in Abuja on Wednesday fixed June 30, 2026, to rule on…
The operatives of the Ogun State Police Command have neutralised two suspected kidnappers, rescued an…
This website uses cookies.